Vertex Pharmaceuticals (VRTX)

"May you live in interesting times."

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Paul Negulescu, Ph.D. Senior Vice President, Vertex has been awarded the 2025 Canada Gairdner Internati...

Berkshire Hathaway led Q1 with a 17.5% return, driven by strong operating earnings and potential for significant acquisitions with over $300 billion in cash. Vertex Pharmaceuticals gained 20.4%, fuele...

Contrary to what you might read on social media, Warren Buffett isn't a fan of tariffs. Berkshire Hathaway even recently took the unusual step of issuing a press release refuting social media claims t...

Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.

Equity markets may be struggling because of President Donald Trump's current economic policies, but that doesn't mean investors should avoid buying stocks right now -- quite the contrary. History tell...

Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex Pharmaceuticals (VRTX 0.75%). Compared to the S&P 500 index, which is down about 16% f...

With the latest approval, Vertex's Kaftrio is now eligible to treat about 4,000 people living in the EU with rare mutations of cystic fibrosis.

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2025 financial results on Monday, May 5, 2025 after the financial markets close. The company w...

Vertex Pharmaceuticals Inc. VRTX is giving investors some good news — especially if they're keeping a close eye on its newly launched painkiller Journavx.